FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, specifically to bispecific antibodies to human CD20 and human transferrin receptor, it can be used in medicine.
EFFECT: obtained antibodies consisting of two pairs of light and two pairs of heavy antibody chains and a Fab fragment fused with a heavy chain with SEQ ID NO: 6-9, SEQ ID NO: 1-3, 10, SEQ ID NO: 11-13, 22 or SEQ ID NO: 14-17 can be used to bind CD20 and transferrin receptor.
7 cl, 7 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BISPECIFIC ANTIBODIES TO HUMAN BETA-AMYLOID / HUMAN TRANSFERRIN RECEPTOR AND METHODS OF USING THEM | 2016 |
|
RU2730682C1 |
| BISPECIFIC ANTIBODY AGAINST CD3E/BCMA AND ITS USE | 2019 |
|
RU2800164C2 |
| HUMAN TSLP ANTIBODIES AND USE THEREOF | 2021 |
|
RU2825460C1 |
| BISPECIFIC ANTIBODY AGAINST RABIES VIRUS AND ITS APPLICATION | 2019 |
|
RU2764740C1 |
| HUMAN ANTIBODIES BINDING TO ROR2 | 2018 |
|
RU2784586C2 |
| ANTIBODY TO CD3 AND ITS PHARMACEUTICAL USE | 2019 |
|
RU2802272C2 |
| TETANUS TOXIN ANTIBODY AND USE THEREOF | 2020 |
|
RU2815280C1 |
| MOLECULES BINDING WITH CD38 AND PD-L1 | 2017 |
|
RU2764201C2 |
| CANINIZED ANTI-HUMAN CTLA-4 ANTIBODIES | 2020 |
|
RU2822460C2 |
| HUMAN TLR7 ANTIBODY | 2019 |
|
RU2808123C2 |
